Journal of Infectious Diseases published new progress about 637-07-0. 637-07-0 belongs to chlorides-buliding-blocks, auxiliary class Inhibitor,Cell Cycle,PPAR, name is Ethyl 2-(4-chlorophenoxy)-2-methylpropanoate, and the molecular formula is C12H15ClO3, Product Details of C12H15ClO3.
Chambers, Henry F. published the artcileRifabutin to the rescue?, Product Details of C12H15ClO3, the publication is Journal of Infectious Diseases (2020), 222(9), 1422-1424, database is CAplus and MEDLINE.
A review. Rifampin as the most interesting new antibiotic, specifically noting its in vitro activity against methicillin-resistant staphylococci and its good oral bioavailability. Administration of rifampin in combination with another active agent was found to prevent emergence of resistance. The activity of rifampin against bacteria within biofilms is a strong rationale for current recommendations for its use in combination therapy to treat device-related staphylococcal infections, eg, prosthetic joint infections, spinal implant infections, prosthetic-valve endocarditis, cerebrospinal fluid shunt infections. A partial list includes anticonvulsants, antiarrhythmics, antiestrogens, antipsychotics, oral anti- coagulants, antifungals, antibacterials, antiretrovirals, barbiturates, β-blockers, benzodiazepines and related drugs, calcium channel blockers, corticosteroids, cardiac glycosides preparations, clofibrate, oral contraceptives, estrogens, oral hypo- glycemic agents, immunosuppressive agents, levothyroxine, losartan, narcotic analgesics, methadone, progestins, selective 5-HT3 receptor antagonists, statins, theophylline, thiazolidinediones, and tri- cyclic antidepressants. Rifamycins (eg, rifampin, rifabutin, rifapentine, and refalazil) all have the same mechanism of action. A randomized controlled trial is warranted to define the efficacy and advantages of rifabutin compared with rifampin in combination therapy for device-related infections, so that clinicians will not have to rely on personal experience, anecdotal reports, and data from observational studies, as was the case for decades with rifampin.
Journal of Infectious Diseases published new progress about 637-07-0. 637-07-0 belongs to chlorides-buliding-blocks, auxiliary class Inhibitor,Cell Cycle,PPAR, name is Ethyl 2-(4-chlorophenoxy)-2-methylpropanoate, and the molecular formula is C12H15ClO3, Product Details of C12H15ClO3.
Referemce:
https://en.wikipedia.org/wiki/Chloride,
Chlorides – an overview | ScienceDirect Topics